title: [Assessment of P504S immunohistochemistry in diagnosis and differential diagnosis of prostatic adenocarcinoma].
abstract: OBJECTIVE
  To assess the utility of P504S immunohistochemistry in the diagnosis and differential diagnosis of prostatic adenocarcinoma.
  
  
  METHODS
  Light microscopy and immunohistochemistry examinations (EnVision staining) were performed in 117 cases of prostatic adenocarcinoma, PIN, AAH, ASAP, BPH and normal prostatic tissue to correlate the morphology and protein expression of P504S, 34betaE12, and P63.
  
  
  RESULTS
  Seventy-one of the 78 (91%) cases of prostatic adenocarcinoma stained positive for P504S, with strong cytoplasmic granular staining in most cases, and a weak or intense granular staining along the circumferential luminal and apical cell border membrane in a few cases. Negative P504S immunostaining was observed in 7 of 78 (9%) cases of prostatic adenocarcinoma, all of which were clear cell type prostatic adenocarcinoma. Cases of PIN (9 cases), AAH (6 cases) and ASAP (2 cases) showed various expression levels of P504S. Sixty-five of 68 (96%) cases of normal prostates and BPH were negative for P504S and basal cell hyperplasia cases were also negative.
  
  
  CONCLUSIONS
  P504S is a useful marker for microscopic diagnosis of prostatic adenocarcinoma, and immunohistochemistry study using a combination of P504S and 34betaE12/p63 may be of greater benefit in aiding the differential diagnoses.
authors.affiliation: Department of Pathology, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050, China.
authors.forename: Guang-yong
authors.initials: GY
authors.lastname: Chen
authors.forename: Li-na
authors.initials: LN
authors.lastname: Liu
authors.forename: Xiao-ge
authors.initials: XG
authors.lastname: Zhou
authors.forename: Chang-huai
authors.initials: CH
authors.lastname: Zhang
authors.forename: Shou-fang
authors.initials: SF
authors.lastname: Huang
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis*; D004268:DNA-Binding Proteins; D003937:Diagnosis, Differential; D016147:Genes, Tumor Suppressor; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008297:Male; D010750:Phosphoproteins / Q000032:analysis; D011230:Precancerous Conditions / Q000175:diagnosis*; D011467:Prostate / Q000201:enzymology; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D019998:Racemases and Epimerases / Q000032:analysis*; D015534:Trans-Activators / Q000032:analysis; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins
chemical_list: C121278:CK-34 beta E12; D004268:DNA-Binding Proteins; D010750:Phosphoproteins; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D007633:Keratins; D019998:Racemases and Epimerases; C108352:alpha-methylacyl-CoA racemase